SLC1A5 and cancer: These include depleting cancer cell glutamine supply (L-asparaginase in acute lymphoblastic leukemia), inhibiting cancer cell glutamine uptake (inhibition of the c-Myc-regulated transporter SLC1A5), use of glutamine mimetics (6-diazo-5-oxo-L-norleucine, acivicin, azaserine) and use of selective glutamines inhibitors (968 and BPTES) (Lukey et al., 2013).